Entera Bio Ltd.

General Information

We are a clinical stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. We are initially applying our technology to develop an oral formulation of parathyroid hormone, or PTH, which has been approved in the United States in injectable form for over a decade. Our lead oral PTH product candidate, EB612, has successfully completed a Phase 2a trial for hypoparathyroidism, a rare condition in which the body fails to produce sufficient amounts of PTH. The FDA and the EMA have granted EB612 orphan drug designation for the treatment of hypoparathyroidism.

Employees: 16
Founded: 2009
Contact Information
Address Kiryat Hadassah, Minrav Building – Fifth Floor, Jerusalem 9112002, Israel
Phone Number +972 (2) 532-7151.
Web Address http://www.enterabio.com
View Prospectus: Entera Bio Ltd.
Financial Information
Market Cap $81.4mil
Revenues $0 mil (last 12 months)
Net Income $-8.28 mil (last 12 months)
IPO Profile
Symbol ENTX
Exchange NASDAQ
Shares (millions): 1.4
Price range $8.00 - $8.00
Est. $ Volume $11.2 mil
Manager / Joint Managers Maxim Group
CO-Managers Joseph Gunnar
Expected To Trade: 6/28/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change